Recurrent Disease

GTD is a highly curable disease. Women with hydatidiform mole have an excellent prognosis and women with malignant GTD (called GTN) usually have a very good prognosis. Choriocarcinoma, for example, is an uncommon, yet almost always curable cancer. Although choriocarcinoma is a highly malignant tumor and life-threatening disease, it is very sensitive to chemotherapy. 85-90% of women with low-risk malignant GTD are cured by the initial chemotherapy and the remaining are cured by the use of stronger combinations of drugs or surgery. Similarly, 85-90% of women who develop high-risk malignant GTD are cured by chemotherapy used together with the selective use of surgery and radiation. Approximately 10-15% of women with high-risk malignant GTD will develop drug resistance after prolonged chemotherapy. This group is made up of patients with stage IV disease that involves distant organs such as the brain, liver and bowel. Specially designed chemotherapy treatments using drugs that have been shown to be effective against other cancers are being employed to prolong life for many of these women.

Spotlight

Women Magazine released a special report on ovarian cancer, featuring Q&A’s with three expert SGO surgeons and important facts about the disease.

Awareness

This year’s GCAM awareness is focused on the important link between obesity and endometrial cancer. Check out the new toolkit to learn more.

Research

The Foundation for Women’s Cancer is pleased to share its 2014-2015 Research Grants and Awards booklet. The booklet describes the prizes and the application process. Prize applications are due on October 8, 2014.

Education

The next Ovarian Cancer Survivors Course will be Saturday, Sept. 20, 2014 in Columbus, Ohio. For more information on educational events and courses, click here.